AMI Cardiogenic Shock

Clinical Evidence

Best Practice Protocols Include <sup>1-4</sup>

Identify CS early and Impella pre-PCI < 90 minutes
Aggressive down-titration of inotropes
Identify RV dysfunction early and support
Identify inadequate LV support and escalate
Systematic use of RHC to guide therapy

81% Survival at 30 Days in a Multi-Center, Multi-Society Study of Impella®-Supported AMI Cardiogenic Shock Patients

Junya Ako, MD, presents data from 593 consecutive patients with AMI cardiogenic shock (AMICS) supported with Impella heart pumps at 109 centers in Japan between October 2017 (when Impella heart pump was introduced in Japan) through January 2020.

Learn More

Impella Clinical Evidence has Established Safety and Effectiveness and Validated Best Practices

Ongoing and Upcoming Clinical Trials

RECOVER IV Randomized Controlled Trial

Upcoming trial to assess whether Impella pre-PCI is superior to PCI without Impella in patients with AMI cardiogenic shock.

Learn More

DanGer Shock Randomized Controlled Trial

Ongoing trial assessing primary outcome of death from all causes at six months with Impella CP® compared to standard of care.

Learn More

The Procedure

Learn more about femoral access explant techniques and other best practices.

References

Tehrani, B. et al. (2019). J Am Coll Cardiol, 73(13), 1659–1669.
O’Neill, W., et al. (2020). TCT Connect.
Basir, B., et al. (2021). SCAI Scientific Sessions.
Ako, J. (2022). TCT. AMICS with Impella-only Support.

NPS-1187